Table 1.
n= | FOXO1 | FOXO3 | |
---|---|---|---|
Total population | |||
Median (range) | 218 | 1.0 (0.07–1.91) | 1.0 (0.19–3.98) |
Low level (%)a | 23 (10.6) | 16 (7.3) | |
High level (%)a | 0 (0) | 13 (6.0) | |
HR− ERBB2− | |||
Median (range) | 44 | 1.03 (0.11–1.91) | 0.84 (0.39–2.52) |
Low level (%)a | 3 (6.8) | 4 (9.1) | |
High level (%)a | 0 (0) | 1 (2.3) | |
HR- ERBB2+ | |||
Median (range) | 42 | 1.11 (0.46–1.81) | 0.98 (0.41–2.77) |
Low level (%)a | 1 (2.4) | 2 (4.8) | |
High level (%)a | 0 (0) | 3 (7.1) | |
HR + ERBB2− | |||
Median (range) | 112 | 0.95 (0.12–1.76) | 1.08 (0.19–3.98) |
Low level (%)a | 16 (14.3) | 9 (8.0) | |
High level (%)a | 0 (0) | 8 (7.1) | |
HR + ERBB2 + | |||
Median (range) | 20 | 1.03 (0.07–1.66) | 1.00 (0.45–2.67) |
Low level (%)a | 3 (15.0) | 1 (5.0) | |
High level (%)a | 0 (0) | 1 (5.0) |
Protein levels were normalized so that the median of values in the 218 breast tumours was 1.
aLow and high protein levels were defined as twofold variations of level, relative to the median level of the series of 218 breast tumors.